Seres Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Seres Therapeutics (Nasdaq: MCRB) will present a corporate overview at the 39th Annual J.P. Morgan Healthcare Conference on January 14 at 11:40 a.m. ET. A live audio webcast will be accessible in the ‘Investors and Media’ section of their website, with a replay available an hour post-event for 21 days.

Seres is focused on microbiome therapeutics, with its SER-109 program achieving positive pivotal clinical results for C. difficile infection and receiving FDA Breakthrough Therapy status. Other programs include SER-287 for ulcerative colitis and SER-401 for metastatic melanoma.

Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced that it will present a corporate overview at the 39th Annual J.P. Morgan Healthcare Conference on Thursday, January 14 at 11:40 a.m. ET.

A live audio webcast of the presentation will be available under the “Investors and Media” section of Seres’ website. A replay of the presentation will become available approximately one hour after the event and will be archived for 21 days.

About Seres Therapeutics

Seres Therapeutics, Inc., (Nasdaq: MCRB) is a leading microbiome therapeutics platform company developing a novel class of multifunctional bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. Seres’ SER-109 program achieved the first-ever positive pivotal clinical results for a targeted microbiome drug candidate and has obtained Breakthrough Therapy and Orphan Drug designations from the FDA. The SER-109 program is being advanced for the treatment of recurrent C. difficile infection and has potential to become a first-in-class FDA-approved microbiome therapeutic. Seres’ SER-287 program has obtained Fast Track and Orphan Drug designations from the FDA and is being evaluated in a Phase 2b study in patients with active mild-to-moderate ulcerative colitis. Seres is evaluating SER-401 in a Phase 1b study in patients with metastatic melanoma, SER-301 in a Phase 1b study in patients with ulcerative colitis and SER-155 to prevent mortality due to gastrointestinal infections, bacteremia and graft versus host disease. For more information, please visit www.serestherapeutics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210106005261/en/

FAQ

When is Seres Therapeutics presenting at the J.P. Morgan Healthcare Conference?

Seres Therapeutics will present on January 14 at 11:40 a.m. ET.

Where can I watch the Seres Therapeutics presentation?

The presentation will be available via a live audio webcast on Seres’ website.

What is SER-109 and its significance for MCRB?

SER-109 is a microbiome therapeutic for recurrent C. difficile infection and has received FDA Breakthrough Therapy designation.

What other programs is Seres Therapeutics currently developing?

Seres is also working on SER-287 for ulcerative colitis, SER-401 for metastatic melanoma, and SER-155 to prevent gastrointestinal infections.

What notable designations has Seres Therapeutics received?

Seres has received Breakthrough Therapy and Orphan Drug designations from the FDA for its SER-109 program.